New Drug Approvals Archive for 2002
Faslodex (fulvestrant) Injection
Date of Approval: April 25, 2002
Treatment for: Breast Cancer
Faslodex (fulvestrant) is an estrogen receptor antagonist indicated for the treatment of hormone receptor positive metastatic breast cancer.
Lexapro (escitalopram oxalate) Tablets and Oral Solution
Date of Approval: August 14, 2002
Company: Allergan, Inc.
Treatment for: Depression, Generalized Anxiety Disorder
Lexapro (escitalopram oxalate) is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder and for the treatment of generalized anxiety disorder (GAD).
Pegasys (peginterferon alfa-2a) Injection
Date of Approval: October 16, 2002
Company: Hoffmann-La Roche
Treatment for: Hepatitis C
Pegasys (peginterferon alfa-2a) is a covalent conjugate of recombinant alfa-2a interferon indicated for the combination treatment of adults with chronic hepatitis C.
Humira (adalimumab) Injection
Date of Approval: December 31, 2002
Company: Abbvie, Inc.
Treatment for: Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease, Acute, Crohn's Disease, Maintenance, Psoriasis, Juvenile Idiopathic Arthritis, Ulcerative Colitis, Hidradenitis Suppurativa, Uveitis
Humira (adalimumab) is a recombinant human IgGl monoclonal antibody specific for human tumor necrosis factor (TNF) indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, juvenile idiopathic arthritis, ulcerative colitis, hidradenitis suppurativa, and certain types of uveitis.
New drug approvals archive
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.